The surprising, aggressive billing practices of Zuckerberg Hospital

Surprise billing has become a serious issue among healthcare consumers who are frequently stuck with a bill for thousands of dollars after receiving care. The practice of surprise billing is largely caused by wide fluctuations in healthcare prices around the country for services.

Another reason may be that some hospitals have their own policy of keeping all private insurers out of network.

That’s the case with Zuckerberg San Francisco General Hospital, the largest public hospital in San Francisco, Vox reported. By not participating in the networks of any private health insurers, patients who are privately insured are left with sky-high medical bills if they receive care there.

As the city’s largest trauma center, about one-third of all ambulances bring patients there, meaning consumers likely don’t have the ability to determine if they will receive out-of-network care before they arrive at the hospital.

According to the hospital, which was renamed after Facebook founder Mark Zuckerberg donated $75 million, its practices are not unusual and aim to serve those covered by public insurance. Others disagree, arguing most other public trauma centers accept several private health insurance plans.

The billing practices were uncovered as part of Vox’s ongoing investigations into ER medical bills.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.